George Lolay, MD
Cardiovascular Disease · Indianapolis, INNPI 1811333941
Payments from drug & device makers
Across 372 payments — averaging $721.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$203K
- Boston Scientific$55K
- Abbott$4K
- Edwards Lifesciences$1K
- Johnson & Johnson$653
- AstraZeneca$542
- plus $3K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 115 | $203,432 |
| Boston Scientific | 31 | $55,153 |
| Abbott | 32 | $3,833 |
| Edwards Lifesciences | 8 | $1,477 |
| Johnson & Johnson | 20 | $653 |
| AstraZeneca | 28 | $542 |
| Novartis | 34 | $540 |
| Heartflow, Inc. | 5 | $448 |
| Pfizer | 29 | $447 |
| Novo Nordisk | 11 | $316 |
| Amgen | 15 | $254 |
| Siemens Medical Solutions USA, Inc. | 2 | $228 |
| Astellas Pharma US Inc | 2 | $198 |
| Boehringer Ingelheim | 5 | $173 |
| Cardiovascular Systems Inc. | 1 | $128 |
| Merck | 8 | $123 |
| GE HealthCare | 1 | $79 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $64 |
| Regeneron Healthcare Solutions, Inc. | 3 | $49 |
| Amarin Pharma, Inc. | 1 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Bayer | 2 | $35 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Terumo Medical Corporation | 1 | $22 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Aegerion Pharmaceuticals, Inc. | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $15 |
How this compares
$268,460 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Indianapolis
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Vijay RaoIndianapolis$706K
- Roopa RaoIndianapolis$481K
- Julie ClaryIndianapolis$475K
- James TrippiIndianapolis$449K
- John MillerIndianapolis$354K
- Richard KovacsIndianapolis$338K
- David KovacichIndianapolis$327K
- Jose Emanuel FinetIndianapolis$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.